These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

190 related articles for article (PubMed ID: 11404233)

  • 1. Exendin-4 reduces fasting and postprandial glucose and decreases energy intake in healthy volunteers.
    Edwards CM; Stanley SA; Davis R; Brynes AE; Frost GS; Seal LJ; Ghatei MA; Bloom SR
    Am J Physiol Endocrinol Metab; 2001 Jul; 281(1):E155-61. PubMed ID: 11404233
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Exenatide can reduce glucose independent of islet hormones or gastric emptying.
    Ionut V; Zheng D; Stefanovski D; Bergman RN
    Am J Physiol Endocrinol Metab; 2008 Aug; 295(2):E269-77. PubMed ID: 18492781
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Lack of effect of exendin-4 and glucagon-like peptide-1-(7,36)-amide on insulin action in non-diabetic humans.
    Vella A; Shah P; Reed AS; Adkins AS; Basu R; Rizza RA
    Diabetologia; 2002 Oct; 45(10):1410-5. PubMed ID: 12378382
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Energy intake and appetite are suppressed by glucagon-like peptide-1 (GLP-1) in obese men.
    Näslund E; Barkeling B; King N; Gutniak M; Blundell JE; Holst JJ; Rössner S; Hellström PM
    Int J Obes Relat Metab Disord; 1999 Mar; 23(3):304-11. PubMed ID: 10193877
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Exendin-4 normalized postcibal glycemic excursions in type 1 diabetes.
    Dupré J; Behme MT; McDonald TJ
    J Clin Endocrinol Metab; 2004 Jul; 89(7):3469-73. PubMed ID: 15240633
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Synthetic exendin-4 (exenatide) significantly reduces postprandial and fasting plasma glucose in subjects with type 2 diabetes.
    Kolterman OG; Buse JB; Fineman MS; Gaines E; Heintz S; Bicsak TA; Taylor K; Kim D; Aisporna M; Wang Y; Baron AD
    J Clin Endocrinol Metab; 2003 Jul; 88(7):3082-9. PubMed ID: 12843147
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Mechanism of action of exenatide to reduce postprandial hyperglycemia in type 2 diabetes.
    Cervera A; Wajcberg E; Sriwijitkamol A; Fernandez M; Zuo P; Triplitt C; Musi N; DeFronzo RA; Cersosimo E
    Am J Physiol Endocrinol Metab; 2008 May; 294(5):E846-52. PubMed ID: 18334612
    [TBL] [Abstract][Full Text] [Related]  

  • 8. No effect of glucagon-like peptide-1 on short-term satiety and energy intake in man.
    Long SJ; Sutton JA; Amaee WB; Giouvanoudi A; Spyrou NM; Rogers PJ; Morgan LM
    Br J Nutr; 1999 Apr; 81(4):273-9. PubMed ID: 10999014
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Lixisenatide reduces postprandial hyperglycaemia via gastrostatic and insulinotropic effects.
    Becker RH; Stechl J; Steinstraesser A; Golor G; Pellissier F
    Diabetes Metab Res Rev; 2015 Sep; 31(6):610-8. PubMed ID: 25773712
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The effect of physiological levels of glucagon-like peptide-1 on appetite, gastric emptying, energy and substrate metabolism in obesity.
    Flint A; Raben A; Ersbøll AK; Holst JJ; Astrup A
    Int J Obes Relat Metab Disord; 2001 Jun; 25(6):781-92. PubMed ID: 11439290
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The effects of fiber enrichment of pasta and fat content on gastric emptying, GLP-1, glucose, and insulin responses to a meal.
    Frost GS; Brynes AE; Dhillo WS; Bloom SR; McBurney MI
    Eur J Clin Nutr; 2003 Feb; 57(2):293-8. PubMed ID: 12571662
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Involvement of endogenous glucagon-like peptide-1 in regulation of gastric motility and pancreatic endocrine secretion.
    Witte AB; Grybäck P; Jacobsson H; Näslund E; Hellström PM; Holst JJ; Hilsted L; Schmidt PT
    Scand J Gastroenterol; 2011 Apr; 46(4):428-35. PubMed ID: 21114428
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Effect of Oxyntomodulin, Glucagon, GLP-1, and Combined Glucagon +GLP-1 Infusion on Food Intake, Appetite, and Resting Energy Expenditure.
    Bagger JI; Holst JJ; Hartmann B; Andersen B; Knop FK; Vilsbøll T
    J Clin Endocrinol Metab; 2015 Dec; 100(12):4541-52. PubMed ID: 26445112
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Effects of intravenous glucagon-like peptide-1 on gastric emptying and intragastric distribution in healthy subjects: relationships with postprandial glycemic and insulinemic responses.
    Little TJ; Pilichiewicz AN; Russo A; Phillips L; Jones KL; Nauck MA; Wishart J; Horowitz M; Feinle-Bisset C
    J Clin Endocrinol Metab; 2006 May; 91(5):1916-23. PubMed ID: 16492694
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Glucagon-like peptide 1 has a physiological role in the control of postprandial glucose in humans: studies with the antagonist exendin 9-39.
    Edwards CM; Todd JF; Mahmoudi M; Wang Z; Wang RM; Ghatei MA; Bloom SR
    Diabetes; 1999 Jan; 48(1):86-93. PubMed ID: 9892226
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Once daily injection of exendin-4 to diabetic mice achieves long-term beneficial effects on blood glucose concentrations.
    Greig NH; Holloway HW; De Ore KA; Jani D; Wang Y; Zhou J; Garant MJ; Egan JM
    Diabetologia; 1999 Jan; 42(1):45-50. PubMed ID: 10027577
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Regulation of islet hormone release and gastric emptying by endogenous glucagon-like peptide 1 after glucose ingestion.
    Salehi M; Vahl TP; D'Alessio DA
    J Clin Endocrinol Metab; 2008 Dec; 93(12):4909-16. PubMed ID: 18827000
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The glucagon-like peptide-1 metabolite GLP-1-(9-36) amide reduces postprandial glycemia independently of gastric emptying and insulin secretion in humans.
    Meier JJ; Gethmann A; Nauck MA; Götze O; Schmitz F; Deacon CF; Gallwitz B; Schmidt WE; Holst JJ
    Am J Physiol Endocrinol Metab; 2006 Jun; 290(6):E1118-23. PubMed ID: 16403774
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The insulinotropic effect of acute exendin-4 administered to humans: comparison of nondiabetic state to type 2 diabetes.
    Egan JM; Clocquet AR; Elahi D
    J Clin Endocrinol Metab; 2002 Mar; 87(3):1282-90. PubMed ID: 11889200
    [TBL] [Abstract][Full Text] [Related]  

  • 20. alpha-Glucosidase inhibition (acarbose) fails to enhance secretion of glucagon-like peptide 1 (7-36 amide) and to delay gastric emptying in Type 2 diabetic patients.
    Hücking K; Kostic Z; Pox C; Ritzel R; Holst JJ; Schmiegel W; Nauck MA
    Diabet Med; 2005 Apr; 22(4):470-6. PubMed ID: 15787675
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.